Vext Science (VEXT) Q2 2025 earnings summary

Executive summary

• Achieved record Q2 2025 results with revenue up 59% year over year to $13.4M, adjusted EBITDA rising to $4.1M with a 30% margin, and operating cash flow reaching $4.2M, reflecting strong execution and capital allocation.

• Ohio retail sales grew 86% sequentially, driven by new dispensary consolidations and expansion, with progress toward the state dispensary license cap of eight by early 2026.

• Maintained profitability in Arizona despite a 13.7% market contraction, outperforming state averages through disciplined operations and in-house retail sell-through.

• Cash flow margin reached 31%, among the highest in the industry, with sequential growth expected through 2025.

• Focus remains on scaling Ohio, optimizing Arizona, and converting top-line growth into free cash flow while minimizing external capital needs.

Financial highlights

• Q2 2025 revenue was $13.4M, up from $8.4M in Q2 2024 and $11.6M in Q1 2025.

• Adjusted EBITDA reached $4.1M, up from $1.1M in Q2 2024 and $3.4M in Q1 2025, with a 30% margin.

• Operating cash flow was $4.2M, compared to negative $0.6M in Q2 2024 and $3.1M in Q1 2025; free cash flow was $3.8M.

• Operating expenses remained flat at $5.3M, falling from 63% to 40% of revenue year over year.

• Net debt reduced to $27.1M in Q2 2025, down from $29M in Q1 and $34.7M in Q2 2023.

Outlook and guidance

• On track to reach Ohio's dispensary license cap of eight by early 2026, with additional locations expected to open in Q4 2025, pending regulatory approvals.

• Substantial free cash flow growth expected as Ohio operations scale, with minimal growth capex required in Arizona and limited remaining capex in Ohio.

• Focused on operational discipline, capital-light growth, and delivering long-term shareholder value into 2026.